Aliccia Bollig-Fischer

Aliccia Bollig-Fischer

 Assistant Professor

313-576-8163

bollig@karmanos.org

Aliccia Bollig-Fischer

Office Address

 608 HWCRC
4100 John R.
Detroit, MI 48201

Mentoring

Emily Girsch(Graduated 05/312019 ) 

Research Interests

• Cancer
• Oncogenes
• Systems Biology
• Molecular Biomarkers & Targeted Therapeutics
 

Research Description

The Bollig-Fischer laboratory applies state-of-the-art genomic methodologies, innovative bioinformatics and molecular biology approaches to tackle clinically relevant cancer research challenges. Research in the Bollig-Fischer Laboratory is focused on studying how lifestyle factors, comorbidities and systemic pathophysiology impact oncogene selection and tumorigenesis. Dr. Bollig-Fischer’s recent discovery of an obesity-induced nuclear factor promoting triple-negative breast cancer tumor incidence was highlighted in The National Cancer Institute’s Nutrition Frontiers newsletter (https://prevention.cancer.gov/news-and-events/news/nutrition-frontiers-winter-9).
Building on this discovery, the Bollig-Fischer Laboratory continues to deliver new knowledge of cancer signaling mechanisms that help to explain the observed obesity-breast cancer connection and race-associated breast cancer disparities.
 

Selected Publications

Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells. Mol Oncol. 2019;13:894-908. 

Teslow EA, Bao B, Dyson G, Legendre C, Mitrea C, Sakr W, Carpten JD, Powell I, Bollig-Fischer A. Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells. Mol Oncol. 2018;12:1138-52. 

Mitrea C, Wijesinghe P, Dyson G, Kruger A, Ruden DM, Draghici S, Bollig-Fischer A. Integrating 5hmC and gene expression data to infer regulatory mechanisms. Bioinformatics. 2018;34:1441-7.

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep. 2017;7:44125.

Complete List of Bollig-Fischer Published Work:
https://www.ncbi.nlm.nih.gov/sites/myncbi/14k8Zz_ui6a/bibliography/43876601/public/?sortby=pubDate&sdirection=descending

Education/Training

PhD (2003) Human Physiology, Michigan State University, East Lansing, MI

Courses Taught

CB7240 Principles of Cancer Therapy
CB7300 Cancer Genomics and Data Analysis
CHM 6680/7680 Molecular and Clinical Aspects of Cancer
 

← Return to listing